DEFA14A: LENSAR and Alcon Receive Second Request from FTC, Merger Timeline Extended

LENSAR, Inc. and Alcon Research, LLC received a second request for information from the Federal Trade Commission (FTC) regarding their proposed merger, extending the waiting period under the Hart-Scott-Rodino Act.

Summary

• LENSAR, Inc. and Alcon Research, LLC are undergoing a merger, with Alcon acquiring LENSAR.
• On May 21, 2025, both companies received a second request for additional information from the FTC regarding the merger.
• This second request extends the waiting period imposed by the Hart-Scott-Rodino Antitrust Improvements Act of 1976 until 30 days after both companies substantially comply with the request, unless the period is extended or terminated sooner by the FTC.
• Both companies plan to respond promptly and continue to cooperate with the FTC.
• LENSAR still anticipates the merger will be completed in the second half of 2025, pending regulatory approval and satisfaction of other closing conditions.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative due to the extended regulatory review process, which introduces uncertainty and potential delays to the merger. While both companies are cooperating, the FTC's second request suggests a more thorough investigation is required.

Positives

• Both LENSAR and Alcon are committed to cooperating with the FTC and responding promptly to the Second Request.
• LENSAR continues to expect that the Merger will be completed in the second half of 2025.

Negatives

• The second request from the FTC delays the completion of the merger.
• The merger is subject to regulatory approvals, which are not guaranteed.

Risks

• The merger may not be completed in a timely manner or at all due to regulatory hurdles.
• Required regulatory approvals may not be obtained, may be delayed, or may be subject to unanticipated conditions.
• The anticipated benefits of the merger may not be realized.
• Competing offers for LENSAR could emerge.
• Conditions to the merger may not be satisfied or waived.
• The merger agreement could be terminated, potentially requiring LENSAR to pay a termination fee.
• The announcement or pendency of the merger could negatively impact LENSAR's ability to retain key personnel or its operating results.
• Unexpected costs, charges, or expenses related to the merger could arise.
• Management's time and attention could be diverted to issues relating to the merger.
• Legal proceedings may be instituted against LENSAR following the announcement of the merger.
• LENSAR's stock price may decline significantly if the merger is not consummated.

Future Outlook

LENSAR continues to expect that the Merger will be completed in the second half of 2025, subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction or waiver of the other closing conditions specified in the Merger Agreement.

Management Comments

• LENSAR and Alcon expect to promptly respond to the Second Request and to continue to work cooperatively with the FTC in its review of the Merger.

Industry Context

The merger between LENSAR and Alcon reflects ongoing consolidation trends in the medical device and pharmaceutical industries, where companies seek to expand their product portfolios and market reach through strategic acquisitions.

Stakeholder Impact

• Shareholders face uncertainty regarding the timing and completion of the merger.
• Employees may experience anxiety related to job security and integration plans.
• Customers may be concerned about potential changes in product availability or service quality.
• Suppliers may need to adjust their relationships based on the merged entity's requirements.
• Creditors may reassess the creditworthiness of the combined company.

Next Steps

• LENSAR and Alcon will respond to the Second Request from the FTC.
• The FTC will review the provided information.
• LENSAR will seek stockholder approval for the merger.
• The companies will work to satisfy or waive the remaining closing conditions.
• The merger will be completed upon satisfaction of all conditions and regulatory approvals.

Key Dates

Keywords

Merger, LENSAR, Alcon, FTC, Regulatory Approval, HSR Act, Antitrust, Acquisition